Novo Nordisk SG&A Expenses 2012-2026 | NVO

Novo Nordisk sg&a expenses for the twelve months ending March 31, 2026 were $10.437B, a 4.95% increase year-over-year.

  • Novo Nordisk annual sg&a expenses for 2025 were $10.64B, a 8.91% increase from 2024.
  • Novo Nordisk annual sg&a expenses for 2024 were $9.77B, a 9.23% increase from 2023.
  • Novo Nordisk annual sg&a expenses for 2023 were $8.944B, a 24.62% increase from 2022.

Novo Nordisk SG&A Expenses 2012-2026 | NVO

  • Novo Nordisk annual sg&a expenses for 2025 were $10.64B, a 8.91% increase from 2024.
  • Novo Nordisk annual sg&a expenses for 2024 were $9.77B, a 9.23% increase from 2023.
  • Novo Nordisk annual sg&a expenses for 2023 were $8.944B, a 24.62% increase from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B